Clinical and biochemical determinants of plasma lipid peroxide levels in type 2 diabetes

Annals of Clinical Biochemistry

Volumn 35, Issue 3, 1998, Pages 387-392

  Lawrence, J R ^a   Campbell, G R ^a   Barrington, H ^a   Malcolm, E A ^a   Brennan, G ^a   Wiles, D H ^a   Paterson, J R ^a  

^a DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antioxidant vitamin levels; Glycaemic control; HbA1; Vascular disease ranking

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID PEROXIDE;

ADULT; AGED; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD LEVEL; DIABETES CONTROL; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK; VASCULAR DISEASE;

EID: 0031744860     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329803500307     Document Type: Article

References (25)

1. Evensen SA, Galdal KS, Nilsen E. LDL-induced cytotoxicity and its inhibition by anti-oxidant treatment in cultured human endothelial cells and fibroblasts. Atherosclerosis 1983; 49: 23-30
2. Fogelman AM, Schechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoprotein leads to cholesterol ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980; 77: 2214-8
3. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-8
4. Lyons TJ. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Med 1991; 8: 411-9
5. Sato Y, Hotta N, Sakamato N, Matsuoka S, Oshishi N, Yagi K. Lipid peroxide levels in plasma of diabetic patients. Biochem Med 1979; 21: 104-7
6. Noberasco G, Odetti P, Boerie D, Maiello M, Adezati L. Malondialdehyde (MDA) levels in diabetic subjects. Relationship with blood glucose and glycosylated haemoglobin. Biomed Pharmacother 1991; 45: 193-6
7. Griesmacher A, Kindhauser M, Andert SE, Schreiner W, Toma C, Knoebl P, et al. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med 1995; 98: 469-75
8. Armstrong AM, Chestnutt JE, Gormly MJ, Young IS. The effect of dietary treatment on lipid peroxidation and antioxidant status in newly diagnosed non-insulin-dependent-diabetes. Free Radic Biol Med 1996; 21, 719-26
9. Draper HH, Squires EJ, Mahmoodi H, Wu J, Agarwal S, Hadley M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med 1993; 15: 353-63
10. Reid DD, Brett GZ, Hamilton PJS, Jarrett RJ, Keen H, Rose G. Cardio-respiratory disease and diabetes among middle-aged male civil servants. Lancet 1974; i: 469-73
11. Young IS, Trimble ER. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 1991; 28: 504-8
12. Catignani GL, Bieri JB. Simultaneous determination of retinol and alphatocopherol in serum or plasma by liquid chromatography. Clin Chem 1983; 29: 708-12
13. Jennings PE, Jones AF, Florkowski CM, Lunec J, Barnett AH. Increased diene conjugates in diabetic subjects with microangiopathy. Diabetic Med 1987; 4: 452-6
14. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen P, Halliwell B, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 1997; 40: 647-53
15. Velasquez E, Winocour PH, Kesteven P, Alberti KGMM, Laker MF. Relation of lipid peroxides to macrovascular disease in type 2 diabetes. Diabetic Med 1991; 8: 752-8
16. Niskanen LK, Salonen JT, Nyyssönen K, Uusitupa MIJ. Plasma lipid peroxidation and hyperglycaemia; a connection through hyperinsulinaemia? Diabetic Med 1995; 12: 802-8
17. Maxwell SRJ, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GHG, et al. Antioxidant status in patients with uncomplicated insulin dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Inv 1997; 27: 484-90
18. Diaz MH, Frei B, Vita JA, and Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-16
19. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parkasarathy S, Carea TE, Butter S, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-95
20. Kita T, Nagano Y, Yokode M, Ishii K, Kame N, Ooshima A, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolaemia. Proc Natl Acad Sci USA 1987; 84: 5928-31
21. Barrowcliffe TW, Gutteridge JMC, Gray E. Oxygen radicals, lipid peroxidation and the coagulation system. Agents Actions 1987; 22: 347-8
22. Griffith R, Virella G, Stevenson H, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune-complexes. J Expl Med 1988; 168: 1041-59
23. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7
24. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12
25. Bellomo G, Maggi E, Poli M, Agosta FG, Bolatti P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 1995; 44: 60-6